<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">101129617</journal-id>
<journal-id journal-id-type="pubmed-jr-id">30409</journal-id>
<journal-id journal-id-type="nlm-ta">Genes Brain Behav</journal-id>
<journal-id journal-id-type="iso-abbrev">Genes Brain Behav.</journal-id>
<journal-title-group>
<journal-title>Genes, brain, and behavior</journal-title>
</journal-title-group>
<issn pub-type="ppub">1601-1848</issn>
<issn pub-type="epub">1601-183X</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28239983</article-id>
<article-id pub-id-type="pmc">5543812</article-id>
<article-id pub-id-type="doi">10.1111/gbb.12377</article-id>
<article-id pub-id-type="manuscript">NIHMS857152</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Targeted deletion of GD3 synthase protects against MPTP-induced neurodegeneration</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Akkhawattanangkul</surname>
<given-names>Yada</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Maiti</surname>
<given-names>Panchanan</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Xue</surname>
<given-names>Yi</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Aryal</surname>
<given-names>Dipendra</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wetsel</surname>
<given-names>William C.</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hamilton</surname>
<given-names>David</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fowler</surname>
<given-names>Stephen C.</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>McDonald</surname>
<given-names>Michael P.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Department of Comparative Medicine, University of Tennessee Health Science Center, Memphis, TN 38163</aff>
<aff id="A2">
<label>2</label>Department of Neurology, University of Tennessee Health Science Center, Memphis, TN 38163</aff>
<aff id="A3">
<label>3</label>Department of Anatomy &amp; Neurobiology, University of Tennessee Health Science Center, Memphis, TN 38163</aff>
<aff id="A4">
<label>4</label>Departments of Psychiatry &amp; Behavioral Sciences, Cell Biology, and Neurobiology, Duke University Medical Center, Durham, NC 27710</aff>
<aff id="A5">
<label>5</label>Department of Pharmacology &amp; Toxicology, University of Kansas, Lawrence, KS 66045</aff>
<author-notes>
<corresp id="FN1">Address correspondence to: Mike McDonald, PhD, UTHSC Department of Neurology, 855 Monroe Ave., 415 Link Bldg., Memphis, TN 38163, (901) 448-4648, <email>mike@tennessee.edu</email></corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>13</day>
<month>4</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>18</day>
<month>4</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<month>6</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>6</month>
<year>2018</year>
</pub-date>
<volume>16</volume>
<issue>5</issue>
<fpage>522</fpage>
<lpage>536</lpage>
<!--elocation-id from pubmed: 10.1111/gbb.12377-->
<abstract>
<p id="P1">Parkinson’s disease is a debilitating neurodegenerative condition for which there is no cure. Converging evidence implicates gangliosides in the pathogenesis of several neurodegenerative diseases, suggesting a potential new class of therapeutic targets. We have shown that interventions that simultaneously increase the neuroprotective GM1 ganglioside and decrease the pro-apoptotic GD3 ganglioside—such as inhibition of GD3 synthase (GD3S) or administration of sialidase—are neuroprotective <italic>in vitro</italic> and in a number of preclinical models. In the present study we investigated the effects of GD3S deletion on parkinsonism induced by 1-Methyl-4phenyl-1,2,3,6-tetrahydropyridine (MPTP). MPTP was administered to GD3S−/− mice or controls using a subchronic regimen consisting of three series of low-dose injections (11 mg/kg/day x 5 days each, 3 weeks apart), and motor function was assessed after each. The typical battery of tests used to assess parkinsonism failed to detect deficits in MPTP-treated mice. More sensitive measures—such as the force-plate actimeter and treadmill gait parameters—detected subtle effects of MPTP, some of which were absent in mice lacking GD3S. In wild-type mice MPTP destroyed 53% of the tyrosine-hydroxylase (TH)-positive neurons in the substantia nigra pars compacta (SNc) and reduced striatal dopamine 60.7%. In contrast, lesion size was only 22.5% in GD3S−/− mice and striatal dopamine was reduced by 37.2%. Stereological counts of Nissl-positive SNc neurons that did not express TH suggest that neuroprotection was complete but TH expression was suppressed in some cells. These results demonstrate that inhibition of GD3S has neuroprotective properties in the MPTP model may warrant further investigation as a therapeutic target.</p>
</abstract>
<kwd-group>
<kwd>Parkinson’s disease</kwd>
<kwd>gangliosides</kwd>
<kwd>MPTP</kwd>
<kwd>bradykinesia</kwd>
<kwd>motor function</kwd>
<kwd>neuroprotection</kwd>
<kwd>dopamine</kwd>
<kwd>substantia nigra</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>